rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
These studies offer novel insights into the mechanism of JAK/STAT activation in patients with JAK2-V617F-negative essential thrombocytosis and primary myelofibrosis.
|
26573090 |
2016 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Increased LGALS3 expression was associated with a negative JAK2 V617F status mutation in leucocytes from PMF but not in patients with ET without this mutation.
|
27402956 |
2016 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The TERT rs2736100 A>C SNP strongly correlated to all MPN, regardless of the phenotype (PV, ET or PMF) and major molecular subtype (JAK2 V617F- or CALR-positive).
|
27061303 |
2016 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The Ph negative MPN (PV, ET and PMF) are characterized by the mutation JAK2(V617F) of the JAK2 protein in the auto-inhibitory JH2 domain, which is found in most PV patients and in approximately half of ET and PMF patients.
|
27282563 |
2016 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Somatic mutations in an endoplasmic reticulum chaperone, named calreticulin (CALR), is the second most common mutation in patients with ET and PMF after JAK2 V617F mutation.
|
26697989 |
2016 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
|
26228487 |
2015 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Around 50% of patients with myelofibrosis have the JAK2(V617F) mutation, but almost all patients have aberrant activation of the JAK-STAT signalling pathway.
|
26648193 |
2015 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Four main molecular types of clonal MPN can be distinguished: JAK2(V617F)-positive ET and PV; JAK2 wild-type ET carrying the MPL(515); mutations in the calreticulin (CALR) gene in JAK2/MPL wild-type ET and MF, and a small proportion of JAK2/MPL/CALR wild-type ET and MF patients.
|
25116092 |
2015 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The etiology of myeloproliferative neoplasms (MPN) (polycythemia vera; essential thrombocythemia; primary myelofibrosis) is unknown, however they are associated with a somatic mutation--JAK2 V617F--suggesting a potential role for environmental mutagens.
|
25719551 |
2015 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
JAK2 V617F mutation allele burden and miR-143 expression level resulted higher in PV and IM respect to ET patients.
|
25527813 |
2015 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
This study revealed that CALR mutant essential thrombocythemia is associated with younger age, higher platelet counts, lower erythrocyte counts, leukocyte counts, hemoglobin, and hematocrit, and increased risk of progression to myelofibrosis in comparison with JAK2 V617F-positive essential thrombocythemia.
|
25934766 |
2015 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
|
26130950 |
2015 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), which include essential thrombocythemia, polycythemia vera, and myelofibrosis (MF), are in a new era of molecular diagnosis, ushered in by the identification of the JAK2(V617F) and cMPL mutations in 2005 and 2006, respectively, and the CALR mutations in 2013.
|
25870379 |
2015 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The JAK2 V617F mutation frequency in our PMF patients was similar to those reported previously.
|
26625816 |
2015 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In conclusion, CALR mutation analysis could be a useful diagnostic tool for ET and PMF in 50% of the cases without JAK2 V617F mutations.
|
25729726 |
2015 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Increased levels of JAK2 full-length transcript and a small but significant increase in JAK2 exon 14 skipping, are associated with the JAK2-V617F allele burden in PMF granulocytes.
|
25617626 |
2015 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Calreticulin (CALR) mutations were recently identified in a substantial proportion of persons with essential thrombocythemia (ET) and with primary myelofibrosis (PMF) without JAK2(V617F).
|
25860380 |
2015 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Activation of Janus kinase 2 (JAK2), frequently as a result of the JAK2(V617F) mutation, is a characteristic feature of the classical myeloproliferative neoplasms (MPNs) polycythemia vera, essential thrombocythemia, and myelofibrosis, and it is thought to be responsible for the constitutional symptoms associated with these diseases.
|
25912019 |
2015 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations.
|
25746303 |
2015 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Genomically, the Janus Kinase 2 V617F mutation was observed less often in del(13q) PMF patients (P = .07).
|
26027540 |
2015 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The frequency of the V617F JAK2 mutation was highest in patients with PV where 56 out of 70 cases (80%) carried the mutation, followed by ET with 6 of 24 (25) and IMF with 2 of 16 (12.5%) .
|
26617890 |
2015 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The discovery of the activating JAK2 V617F mutation in patients with myelofibrosis (MF) led to the development of JAK2 inhibitors.
|
24856675 |
2014 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Patients with JAK2 V617F-positive MPN have a heterogeneous histology while CALR-positive ET is associated with megakaryocyte abnormalities and prefibrotic PMF.
|
24957246 |
2014 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We investigated this question using conditional JAK2(V617F) knock-in mice with constitutive and inducible expression of JAK2(V617F) in hematopoietic cells, which develop a polycythemia vera (PV)-like disorder evolving into myelofibrosis.
|
24951423 |
2014 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Mutations of JAK2(V617F) or MPL(W515K/L) were absent in pediatric patients with PMF according to previous studies.
|
25176567 |
2014 |